VRDN
Viridian Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -15.4% ·
share flow +17.0% ·
net new positions -18.2%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 73 | -12 | 71.65M | $1.32B | +6 | −18 |
| Q1 2026 | 88 | +7 | 66.96M | $1.32B | +11 | −5 |
| Q4 2025 | 82 | +2 | 62.58M | $1.95B | +4 | −1 |
| Q3 2025 | 16 | -1 | 34.97M | $754.70M | — | −1 |
| Q2 2025 | 14 | -2 | 33.44M | $467.46M | — | −2 |
| Q1 2025 | 13 | +2 | 10.47M | $141.20M | +2 | — |
| Q4 2024 | 11 | -2 | 10.88M | $208.63M | — | −2 |
| Q3 2024 | 12 | +3 | 5.78M | $131.57M | +3 | — |
| Q2 2024 | 9 | — | 3.15M | $40.97M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 3.52M | — | $67.53M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Adage Capital Partners ✦ | 1.67M | +38.6% | $32.01M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.66M | +11.1% | $31.81M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 1.66M | +11.1% | $31.81M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 1.33M | +2847.7% | $25.44M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 1.33M | +2847.7% | $25.44M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Fisher Asset Management ✦ | 518.03K | +4.7% | $9.93M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | D. E. Shaw & Co. ✦ | 442.07K | +220.2% | $8.47M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Two Sigma Investments ✦ | 424.54K | -11.9% | $8.14M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 10 | Renaissance Technologies ✦ | 371.20K | +522.8% | $7.12M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 11 | Millennium Management ✦ | 365.97K | -45.2% | $7.02M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 358.36K | +48.5% | $6.87M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 358.36K | +48.5% | $6.87M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 14 | Wellington Management ✦ | 224.48K | -4.9% | $4.30M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 15 | Wellington Management ✦ | 224.48K | -4.9% | $4.30M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 16 | Wellington Management ✦ | 224.48K | -4.9% | $4.30M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 17 | Wellington Management ✦ | 224.48K | -4.9% | $4.30M | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Marshall Wace | $15.58M | was 0.0% |
| Point72 Asset Management | $787,766 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 225 holders, 111.32M shares, $2.12B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 4.21K sh · $103,194
Officer · 10.00K sh · $245,000
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology